Keiko Maekawa

Dr. Keiko Maekawa

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2017 in Biochemistry
Verified
Journal Article
Closed access
KMKeiko Maekawa
Keiko Maekawa
MAMotoyasu Adachi
Motoyasu Adachi
YMYumiko Matsuzawa
Yumiko Matsuzawa
QZQinghai Zhang
Qinghai Zhang
RKRyota Kuroki
Ryota Kuroki
MSManish Shah
Manish Shah

6 July 2022 in Chemical Science
Verified
Journal Article
Open access
PDF file
MIMoeko Itoga
Moeko Itoga
MYMasako Yamanishi
Masako Yamanishi
TUTaro Udagawa
Taro Udagawa
AKAyane Kobayashi
Ayane Kobayashi
KMKeiko Maekawa
Keiko Maekawa
HNHiroshi Naka
Hiroshi Naka
An α-selective, iridium(iii)-bipyridonate-catalyzed hydrogen isotope exchange of alcohols using D2O has been developed for the direct, chemoselective deuteration of primary and secondary alcohols, thereby providing deuterated bioactive molecules.

23 August 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
KMKeiko Maekawa
Keiko Maekawa
MRMasaki Ri
Masaki Ri
MNMiki Nakajima
Miki Nakajima
ASAkihiro Sekine
Akihiro Sekine
RURyuzo Ueda
Ryuzo Ueda
SIShinsuke Iida
Shinsuke Iida
Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to this agent. In addition, BTZ‐induced peripheral neuropathy (BiPN), a frequent side‐effect of this therapy, limits its use in some patients. This study aimed to explore serum lipid biomarker candidates to predict the response to BTZ and the severity of BiPN. Fifty‐nine serum samples were collected from patients with MM prior to receiving BTZ plus low‐dose dexamethasone therapy. Serum levels of phospholipids, sphingolipids, neutral lipids, and polyunsaturated fatty acids and their oxidation products were measured by a comprehensive lipidomic study. Overall, 385 lipid metabolites were identified in patients’ sera; lower levels of several glycerophospholipids, sphingolipids, and cholesteryl esters were associated with a poor treatment response. Metabolites related to platelet‐activating factor biosynthesis and cholesterol metabolism appeared particularly relevant. Furthermore, several lysophosphatidylcholines, phosphatidylcholines, ceramides, neutral lipids, and oxidative fatty acids were significantly increased or decreased in patients with BiPN grades ranging from G0 to G3. Among these compounds, mediators reportedly inducing myelin breakdown and stimulating inflammatory responses were prominent. Although further study is necessary to validate these biomarker candidates, our results contribute to the development of predictive biomarkers for response to BTZ treatment, or ensuing severe BiPN, in patients with MM.

1 January 2008 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
SKSu-Ryang Kim
Su-Ryang Kim
YSYoshiro Saito
Yoshiro Saito
KMKeiko Maekawa
Keiko Maekawa
ESEmiko Sugiyama
Emiko Sugiyama
NKNahoko Kaniwa
Nahoko Kaniwa
JSJun-Ichi Sawada
Jun-Ichi Sawada
Deoxycytidine kinase (dCK) is a rate-limiting enzyme in the activation of nucleoside anticancer drugs, such as gemcitabine and cytarabine (Ara-C), to their active metabolites. In this study, the 5'-flanking region, 7 exons and their flanking introns of DCK were comprehensively screened for genetic variations in 256 Japanese cancer patients administered gemcitabine. Twenty-nine genetic variations, including twenty novel ones, were found: 11 in the 5'-flanking region, 1 in the 5'-untranslated region (UTR), 1 in the coding exon, 9 in the 3'-UTR, and 7 in the introns. The novel variations included -1110C>T, -757G>A, -639C>T, -465G>A, -402T>C, -224C>A, -199C>G, IVS1+38G>T, IVS2+78_+83delTTTTTC, IVS3-9C>T, IVS4+12T>C, IVS5+39T>C, 1357A>G, 1545A>T, 1572delA, 1736G>A, 1749G>A, 1838T>C, 1889G>A, and 2048A>T. The frequencies were 0.01 for IVS2+78_ +83delTTTTTC, 0.008 for -402T>C, 0.006 for -639C>T and IVS4+12T>C, 0.004 for -757G>A and 1572delA, and 0.002 for the other 14 variations. A known nonsynonymous SNP 364C>T (Pro122Ser) was detected at a 0.061 frequency. Using the detected polymorphisms, linkage disequilibrium analysis was performed, and 24 haplotypes were identified or inferred. Our findings suggest considerable ethnic differences in genetic variations of DCK and provide fundamental and useful information for genotyping DCK in the Japanese and probably other Asian populations.

14 July 2022 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MRMohammad Sofiqur Rahman
Mohammad Sofiqur Rahman
NYNaoko Yoshida
Naoko Yoshida
MHMiho Hanafusa
Miho Hanafusa
AMAyaka Matsuo
Ayaka Matsuo
SZShu Zhu
Shu Zhu
KKKazuko Kimura
Kazuko Kimura

1 July 2020 in Clinical Therapeutics
Verified
Journal Article
Closed access
MMMika Maeda
Mika Maeda
RTRieko Tanaka
Rieko Tanaka
MAMasako Aso
Masako Aso
YSYasutoshi Sakamoto
Yasutoshi Sakamoto
ISIldae Song
Ildae Song
YKYuji Kumagai
Yuji Kumagai